Combining nab-paclitaxel with radiation therapy for advanced nasopharyngeal carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to identify the maximum tolerated dose and the recommended phase II dose of nab-paclitaxel when given alongside intensity-modulated radiation therapy in patients with stage III-IVa nasopharyngeal carcinoma. Participants will receive varying doses of nab-paclitaxel (180 mg/m², 200 mg/m², 230 mg/m², and 260 mg/m²) while being monitored for toxicity responses. The study focuses on understanding how this combination treatment can improve outcomes for patients with this type of cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathologically confirmed nasopharyngeal carcinoma
* III-IVa (AJCC8th)
* age 18-70
* PS score 0-1
* normal functions to tolerate chemotherapy and radiotherapy

Exclusion Criteria:

* The presence of other malignant neoplasms within the preceding five years, with the exception of carcinoma in situ, adequately treated non-melanoma skin cancer and papillary thyroid cancer, is permitted.
* Symptomatic heart failure, unstable angina, myocardial infarction, active infections requiring systemic therapy, psychiatric disorders, or family and social factors

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Fang-Yun Xie
• Email: xiefy@sysucc.org.cn
• Phone: +8613902205880

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Structured swallowing exercises for nasopharyngeal cancer patients

  This trial tests whether a structured swallowing exercise program improves swallowing and quality of life more than conventional swallowing exercises in adults with nasopharyngeal carcinoma.

  Recruiting Universitas Indonesia · Jakarta Pusat, DKI Jakarta · NCT07909538

• Dynamic risk prediction for severe blood cell suppression in nasopharyngeal cancer

  This study tests a dynamic risk model to see if it can predict grade 3 or higher anemia, low platelets, or low white blood cells during systemic therapy for adults with nasopharyngeal cancer.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07819656

• Becotatug Vedotin plus PD-1 inhibitor for locally recurrent nasopharyngeal carcinoma

  This study tests whether adding becotatug vedotin to a PD-1 inhibitor helps people with locally recurrent nasopharyngeal cancer.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07781358

• Dynamic risk-guided EBV-DNA and MRI-based chemotherapy adjustments in nasopharyngeal carcinoma

  This trial tests whether adjusting adjuvant therapy based on changes in EBV DNA and MRI findings after radiotherapy helps improve outcomes for people with nasopharyngeal carcinoma.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07762976

• Immune Sandwich: Induction with Nimotuzumab and Toripalimab Plus Radiotherapy vs Full-Course Immunotherapy for Advanced Nasopharyngeal Cancer

  This trial tests whether a shortened, targeted immunotherapy plan added to chemoradiation can match the full immunotherapy approach for locally advanced nasopharyngeal cancer in adults 18–70.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07706985

• RAIRI-guided risk-stratified adjuvant therapy after chemoradiotherapy in nasopharyngeal carcinoma

  This real-world study tests whether the RAIRI model can predict who will benefit from adjuvant therapy after chemoradiotherapy for non-metastatic nasopharyngeal carcinoma.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07618078

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.